ReviewCureus2026
Artificial Intelligence in Sports Cardiology: Advancing Cardiovascular Screening and Diagnosis.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sudden cardiac death in athletes, though uncommon, remains a major concern in sports cardiology. Many responsible cardiovascular conditions, including cardiomyopathies, inherited channelopathies, valvular disease, and congenital coronary anomalies, may remain asymptomatic until intense physical exertion. Current pre-participation screening relies on clinical history, physical examination, electrocardiography, and selective cardiac imaging. While effective, these tools are limited by interobserver variability, dependence on specialist expertise, and difficulty distinguishing physiological athletic remodeling from pathological disease. These limitations have prompted growing interest in artificial intelligence (AI) as an adjunct to cardiovascular screening in athletes. This review summarizes current evidence on AI applications in sports cardiology, with a focus on electrocardiography, digital auscultation, transthoracic echocardiography, and selected imaging modalities. AI-enhanced electrocardiographic analysis has demonstrated improved sensitivity compared with traditional criteria for detecting left ventricular hypertrophy, long QT syndrome, including concealed forms, Brugada syndrome, electrolyte abnormalities, and aortic stenosis. Several deep learning models identify disease patterns even when conventional electrocardiographic parameters appear normal, addressing a key limitation of standard screening approaches. AI-assisted digital auscultation improves the detection of pathological murmurs and differentiation from benign flow murmurs, supporting earlier identification of valvular disease. In echocardiography, AI-guided image acquisition and automated analysis improve access, workflow efficiency, and measurement consistency, with diagnostic performance approaching expert interpretation. This review proposes a pragmatic AI-integrated screening framework that complements clinician judgment rather than replacing it. Although promising, limitations remain, including limited athlete-specific training data, false-positive risk related to physiological remodeling, and the need for external validation. When thoughtfully integrated into clinical workflows, AI may enhance early detection of occult cardiac disease and improve cardiovascular risk stratification in athletes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.